Risk of ocular adverse events with aromatase inhibitors

CONCLUSION: Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.PMID:37931898 | DOI:10.1016/j.jcjo.2023.10.013

Source: Canadian Journal of Ophthalmology - November 6, 2023 Category: Opthalmology Authors: Zhao Xun Feng Aswen Sriranganathan Cody Lo Victoria Liu David Maberley Mahyar Etminan Source Type: research